patrick.net
An Antidote to Corporate Media
1,189,967 comments by 13,851 users - GNL, Onvacation, RC2006, Tenpoundbass online now
invite response« First « Previous Comments 3 - 23 of 23 Search these comments
3
Patrick
2022 May 7, 4:47pm
Patrick
2022 May 7, 4:47pm
@CBOEtrader Your buddy should be telling everyone he knows about this.
I think it is far, far more common than more people realize.
You probably know my wife's co-worker dropped dead after the vaxx, and also a friend of ours got myocarditis after the vaxx.
Neither of which was officially reported as a side effect of the vaxx.
I think it is far, far more common than more people realize.
You probably know my wife's co-worker dropped dead after the vaxx, and also a friend of ours got myocarditis after the vaxx.
Neither of which was officially reported as a side effect of the vaxx.
4
Patrick
2022 May 7, 4:49pm
Patrick
2022 May 7, 4:49pm
https://www.theepochtimes.com/does-the-covid-jab-kill-more-people-than-it-saves_4442858.html?source=patrick.net&utm_source=share-btn-copylink
Does the COVID Jab Kill More People Than It Saves?
U.K. government data show the all-cause mortality rate is between 100% and 300% greater among people who got their first COVID shot 21 days or more ago. The risk for all-cause death is also significantly elevated among those who got their second dose at least six months ago, and mildly elevated among those who got their third dose less than 21 days ago. As of January 2022, all who got one or more doses at least 21 days ago were dying at significantly elevated rates
According to U.S. Centers for Disease Control and Prevention data,[1] more than 1 million excess deaths — that is, deaths in excess of the historical average — have been recorded since the COVID-19 pandemic began two years ago, and this cannot be explained by COVID-19.
Deaths from heart disease, high blood pressure, dementia and many other illnesses rose during that time.[2] “We’ve never seen anything like it,” Robert Anderson, CDC’s head of mortality statistics, told The Washington Post in mid-February 2022.[3]
According to University of Warwick researchers, “the scale of excess non-COVID deaths is large enough for it to be seen as its own pandemic.”[4] A number of explanations have been offered, including the fact that lockdowns and other COVID restrictions discouraged or prevented people from seeking care. But another, less discussed factor may also be at play.
Across the world, death rates have risen in tandem with COVID shot administration, with the most-jabbed areas surpassing the least-jabbed in terms of excess mortality and COVID-related deaths. This flies in the face of official claims that the shots prevent severe COVID infection and lower your risk of death, be it from COVID or all causes.[5]
5
CBOEtrader
2022 May 7, 6:30pm
CBOEtrader
2022 May 7, 6:30pm
DooDahMan says
My buddy has no reason to lie about his father’s death. His father was a very high net worth dem doner. They are a prominent democrat family and the son confided in me.
I certainly wouldn’t be a witness in a courtroom. This is more like water cooler talk.
You appear to be a troll. Try adding something of value before I block you
CBOEtrader saysAfter hearing this, my buddy asks them if they think the booster killed his father. They said yes, but their opinions on the booster had to be kept private and no mention was allowed in official death documents.
Drama + Drama = More Drama
Even Judge Judy would not accept this "heresay" evidence.
I call bullshit with a capital "B" and then some
My buddy has no reason to lie about his father’s death. His father was a very high net worth dem doner. They are a prominent democrat family and the son confided in me.
I certainly wouldn’t be a witness in a courtroom. This is more like water cooler talk.
You appear to be a troll. Try adding something of value before I block you
6
mell
2022 May 7, 7:01pm
DooDahMan says
No. These types of autoimmune diseases do not kill quickly, people can have "relatively normal" lives with Lupus. This is a spike protein production dial turned to 11 on a scale of 1 to 10, probably with mrna lodged within multiple organs.
CBOEtrader saysbody’s immune response attacked his own organs
Any chance of undiagnosed Lupus or Autoimmune Disease ?
No. These types of autoimmune diseases do not kill quickly, people can have "relatively normal" lives with Lupus. This is a spike protein production dial turned to 11 on a scale of 1 to 10, probably with mrna lodged within multiple organs.
7
PeopleUnited
2022 May 7, 10:36pm
PeopleUnited
2022 May 7, 10:36pm
CBOEtrader says
Don’t hold your breath, doodipshit won’t be providing something resembling value any sooner than the vax will. First clue? What kind of dipshit posts meaningless article after article of mainstream media bulshit? An NPC of course.
Try adding something of value before I block you
Don’t hold your breath, doodipshit won’t be providing something resembling value any sooner than the vax will. First clue? What kind of dipshit posts meaningless article after article of mainstream media bulshit? An NPC of course.
8
mell
2022 May 8, 1:32pm
DooDahMan says
The OP
mell saysThis is a spike protein production dial turned to 11 on a scale of 1 to 10, probably with mrna lodged within multiple organs.
Based on what ?
The OP
9
Al_Sharpton_for_President
2022 May 8, 1:49pm
Al_Sharpton_for_President
2022 May 8, 1:49pm
To the Editor:
We read with interest the article: “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?ˮ by Bril F. et al. 1 and the comment to the letter by Capecchi L. et al. recently published in J Hepatol.2
Although the onset of autoimmune hepatitis (AIH) in a young woman in the post-partum period, the presence of eosinophils at liver histology, and the short period elapsed after vaccine administration may support a coincidental association between AIH and SARS-CoV-2 vaccine,2 we recently observed a case of an 80-year-old woman who developed AIH 1 week after completing the schedule of Pfizer-BioNTech BNT162b2 mRNA vaccination. She was referred to our institution because of the recent onset of jaundice, hyperchromic urine, and elevated liver enzymes. The patient did not report smoking or alcohol use. Medical history included Hashimoto's thyroiditis on treatment with levothyroxine and an episode of acute glomerulonephritis in 1995 regressed after a cycle of corticosteroids. Current therapy was cholesterol-lowering pravastatin and aspirin for primary cardiovascular prevention. Physical examination was normal except for jaundice. Laboratories were significant for aspartate aminotransferase (AST) (1,401 IU/L; nl 0–40), alanine aminotransferase (ALT) (1,186 IU/L; nl 0–40) bilirubin (total 10.5 mg/dl; direct 7.5 mg/dl), alkaline phosphatase (ALP) (243 IU/L; nl 30-120) and gamma-glutamyl transferase (GGT) (524 IU/L; nl 7-44).
Hepatitis A, B, and C virus markers and HIV, Cytomegalovirus, Epstein Barr, Herpes simplex type 1 and 2 serology were negative. Ceruloplasmin and α1-antitrypsin levels were normal. The anti-mitochondrial, anti-smooth muscle, anti-liver-kidney microsomal antibodies were negative, while the antinuclear antibody (ANA) was positive (1:160, speckled pattern). Total IgG was 3,500 mg/dl (normal range: 750–1,600 mg/dl). Abdominal ultrasound showed enlarged reactive hilar lymph nodes (diameter up to 31 mm). Interface hepatitis with a moderate degree of lymphoplasmacytic infiltrate and multiple confluent foci of lobular necrosis with Councilman bodies were found at liver histology. According to the International Autoimmune Hepatitis Group (IAIHG) criteria,3 the patient's pre-treatment score was 19. The patient started a treatment schedule with prednisone at a dose of 1 mg/kg/day and subsequent tapering of 10 mg/week with a progressive improvement of the laboratory tests (Fig. 1 ).
ALT, alanine aminotransferase; AST, aspartate aminotransferase. (This figure appears in color on the web.)
Several pathogens, such as Epstein–Barr, varicella-zoster, and hepatitis A viruses, can trigger AIH onset.4 In addition, some reports described a relationship between vaccination (i.e., hepatitis A and influenza virus) and the development of AIH,[5], [6], [7], [8] suggesting a potential role of both virus and vaccine in unmasking AIH in predisposed individuals. Thus, the occurrence of acute or chronic liver disease following viral infection or vaccination should raise the suspicion of AIH in the presence of other autoimmune disorders.
Although the causal link between the SARS-CoV-2 vaccine and AIH cannot be definitively established, our case report suggests that this association could be more than coincidental. Indeed, the medical history negative for liver disease as well as the coexistence of another autoimmune disorder, the reasonable lag time between exposure to the triggering factor, the typical onset of symptoms, the laboratory/histopathological findings and finally the excellent response to therapy are all pieces of the puzzle that reinforce the hypothesis of an association between AIH and SARS-CoV-2 vaccination.
In summary, since the vaccination campaign against SARS-CoV-2 is reaching extraordinary coverage rates, healthcare providers should be aware of the potential association between the vaccine and the onset of immunomediated disorders in patients with a history of autoimmune diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/?source=patrick.net
We read with interest the article: “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?ˮ by Bril F. et al. 1 and the comment to the letter by Capecchi L. et al. recently published in J Hepatol.2
Although the onset of autoimmune hepatitis (AIH) in a young woman in the post-partum period, the presence of eosinophils at liver histology, and the short period elapsed after vaccine administration may support a coincidental association between AIH and SARS-CoV-2 vaccine,2 we recently observed a case of an 80-year-old woman who developed AIH 1 week after completing the schedule of Pfizer-BioNTech BNT162b2 mRNA vaccination. She was referred to our institution because of the recent onset of jaundice, hyperchromic urine, and elevated liver enzymes. The patient did not report smoking or alcohol use. Medical history included Hashimoto's thyroiditis on treatment with levothyroxine and an episode of acute glomerulonephritis in 1995 regressed after a cycle of corticosteroids. Current therapy was cholesterol-lowering pravastatin and aspirin for primary cardiovascular prevention. Physical examination was normal except for jaundice. Laboratories were significant for aspartate aminotransferase (AST) (1,401 IU/L; nl 0–40), alanine aminotransferase (ALT) (1,186 IU/L; nl 0–40) bilirubin (total 10.5 mg/dl; direct 7.5 mg/dl), alkaline phosphatase (ALP) (243 IU/L; nl 30-120) and gamma-glutamyl transferase (GGT) (524 IU/L; nl 7-44).
Hepatitis A, B, and C virus markers and HIV, Cytomegalovirus, Epstein Barr, Herpes simplex type 1 and 2 serology were negative. Ceruloplasmin and α1-antitrypsin levels were normal. The anti-mitochondrial, anti-smooth muscle, anti-liver-kidney microsomal antibodies were negative, while the antinuclear antibody (ANA) was positive (1:160, speckled pattern). Total IgG was 3,500 mg/dl (normal range: 750–1,600 mg/dl). Abdominal ultrasound showed enlarged reactive hilar lymph nodes (diameter up to 31 mm). Interface hepatitis with a moderate degree of lymphoplasmacytic infiltrate and multiple confluent foci of lobular necrosis with Councilman bodies were found at liver histology. According to the International Autoimmune Hepatitis Group (IAIHG) criteria,3 the patient's pre-treatment score was 19. The patient started a treatment schedule with prednisone at a dose of 1 mg/kg/day and subsequent tapering of 10 mg/week with a progressive improvement of the laboratory tests (Fig. 1 ).
ALT, alanine aminotransferase; AST, aspartate aminotransferase. (This figure appears in color on the web.)
Several pathogens, such as Epstein–Barr, varicella-zoster, and hepatitis A viruses, can trigger AIH onset.4 In addition, some reports described a relationship between vaccination (i.e., hepatitis A and influenza virus) and the development of AIH,[5], [6], [7], [8] suggesting a potential role of both virus and vaccine in unmasking AIH in predisposed individuals. Thus, the occurrence of acute or chronic liver disease following viral infection or vaccination should raise the suspicion of AIH in the presence of other autoimmune disorders.
Although the causal link between the SARS-CoV-2 vaccine and AIH cannot be definitively established, our case report suggests that this association could be more than coincidental. Indeed, the medical history negative for liver disease as well as the coexistence of another autoimmune disorder, the reasonable lag time between exposure to the triggering factor, the typical onset of symptoms, the laboratory/histopathological findings and finally the excellent response to therapy are all pieces of the puzzle that reinforce the hypothesis of an association between AIH and SARS-CoV-2 vaccination.
In summary, since the vaccination campaign against SARS-CoV-2 is reaching extraordinary coverage rates, healthcare providers should be aware of the potential association between the vaccine and the onset of immunomediated disorders in patients with a history of autoimmune diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/?source=patrick.net
10
Al_Sharpton_for_President
2022 May 8, 1:51pm
Al_Sharpton_for_President
2022 May 8, 1:51pm
To the Editor:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with the development of autoimmune processes.[1], [2], [3], [4] Molecular mimicry has been suggested as a potential mechanism for these associations.1 In an in vitro study, Vojdani et al. 5 showed that antibodies against the spike protein S1 of SARS-CoV-2 had high affinity against the following human tissue proteins: transglutaminase 3, transglutaminase 2, anti-extractable nuclear antigen, nuclear antigen, and myelin basic protein. As this is the same viral protein that the vaccine mRNA codes for, it is plausible that these vaccines may unmask autoimmune diseases in predisposed patients. Recently, several cases of immune thrombocytopenia (ITP) developing days after COVID-19 vaccination, have been reported to the Vaccine Adverse Event Reporting System (VAERS), reinforcing the possibility of vaccine-induced autoimmunity.6
We have recently treated a 35-year-old Caucasian female in her third month postpartum, who developed autoimmune hepatitis after COVID-19 vaccination. During pregnancy, she was diagnosed with gestational hypertension and started on labetalol 100 mg bid. C-section was performed without any complications, and patient was discharged from the hospital on labetalol for blood pressure control. She resumed her job as a healthcare provider in mid-December, and received her first dose of Pfizer-BioNTech COVID-19 vaccine on January 4th. After 1 week, she started developing generalized pruritus, then choluria, and finally noticed jaundice, presenting to the emergency room on day +13 after COVID-19 vaccination.
She had a normal physical exam, except for scleral icterus, jaundice and palpable hepatomegaly. In the emergency room, laboratories were significant for: bilirubin 4.8 mg/dl, AST 754 U/L, ALT 2,001 U/L, alkaline phosphatase 170 U/L, and ammonium 61 mg/dl. Laboratory results were negative for hepatitis A, B, and C, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV) type 1 and 2, and HIV. At the time of submission, HEV had not been tested. Antinuclear antibody (ANA) was positive (1:1,280; homogeneous pattern). Double-stranded DNA antibodies were also positive (1:80). Other antibodies (i.e. anti-mitochondrial, anti-smooth muscle, liver-kidney microsomal, antineutrophil cytoplasmic antibodies) were negative. Total IgG was 1,081 mg/dl (normal range: 694–1,618 mg/dl). Ceruloplasmin, transferrin saturation, alpha-1-antitrypsin, TSH, and serum protein electrophoresis were all normal. Abdominal ultrasound with Doppler reported hepatomegaly without cirrhotic morphology, and no intra- or extra-hepatic biliary dilation.
Endoscopic ultrasound showed no evidence of biliary lithiasis or biliary dilation, and transduodenal liver biopsies were obtained. In Fig. 1 A–D we have included the slides of her liver biopsy and a full description of the histology. Liver biopsy was consistent with drug/toxin related liver injury, autoimmune hepatitis or infectious related etiologies. A PAS-D stain, CMV & HSV 1/2 immunohistochemical stains, EBV by in situ hybridization (EBER-ISH) and Grocott methenamine special stain for fungi were all negative. Other than the COVID-19 vaccine and labetalol, no other drugs, herbal supplements or toxins were reported by the patient. The Revised Original Score for autoimmune hepatitis pretreatment was 18 (results >15 suggest definite autoimmune hepatitis). Fig. 1E summarizes plasma ALT, AST, and total bilirubin over time, before and after treatment with prednisone 20 mg daily.
To our knowledge, this is the first reported episode of autoimmune hepatitis developing post-COVID-19 vaccination, raising concern regarding the possibility of vaccine-induced autoimmunity. As causality cannot be proven, it is possible that this association is just coincidental. However, severe cases of SARS-CoV-2 infection are characterized by an autoinflammatory dysregulation that contributes to tissue damage.1 As the viral spike protein appears to be responsible for this,1 , 5 it is plausible that spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals. In support of this, several cases of ITP have been reported days after COVID-19 vaccination.6
Several atypical features of her presentation deserve further discussion. First, immunoglobulin G levels were not elevated as typically reported for autoimmune hepatitis. However, Hartl et al. recently reported that ~10% of patients with autoimmune hepatitis had normal immunoglobulin G levels at presentation.7 Second, histology revealed the presence of eosinophils, which are more commonly seen with drug or toxin induced liver injury. However, they can be found in cases of autoimmune hepatitis.8 It is also possible that we could be in the presence of a vaccine-related drug-induced liver injury with features of autoimmune hepatitis, as previously described for nitrofurantoin or minocycline.9 In line with this, the patient has already started a prednisone taper, as patients with well documented drug-induced AIH do not typically show relapses after steroid discontinuation.10 Finally, symptoms developed 6 days after vaccination, which instinctively appears as a short period of time. However, latency periods after vaccination of just days have been observed in prior reports.6 , 11
In summary, autoimmune hepatitis developed in a healthy 35-year-old female in her third month postpartum. Whether there exists a causal relationship between COVID-19 vaccination and the development of autoimmune hepatitis remains to be determined. We are hopeful that this manuscript will not discourage healthcare providers from getting and prescribing COVID-19 vaccines, but that it will raise awareness about potential side effects that will likely emerge as we continue to vaccinate more people. Only long-term follow-up of large cohorts of patients receiving the vaccine will answer the question as to whether it increases the risk of autoimmune conditions. Until then, healthcare providers are encouraged to remain vigilant.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/?source=patrick.net
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with the development of autoimmune processes.[1], [2], [3], [4] Molecular mimicry has been suggested as a potential mechanism for these associations.1 In an in vitro study, Vojdani et al. 5 showed that antibodies against the spike protein S1 of SARS-CoV-2 had high affinity against the following human tissue proteins: transglutaminase 3, transglutaminase 2, anti-extractable nuclear antigen, nuclear antigen, and myelin basic protein. As this is the same viral protein that the vaccine mRNA codes for, it is plausible that these vaccines may unmask autoimmune diseases in predisposed patients. Recently, several cases of immune thrombocytopenia (ITP) developing days after COVID-19 vaccination, have been reported to the Vaccine Adverse Event Reporting System (VAERS), reinforcing the possibility of vaccine-induced autoimmunity.6
We have recently treated a 35-year-old Caucasian female in her third month postpartum, who developed autoimmune hepatitis after COVID-19 vaccination. During pregnancy, she was diagnosed with gestational hypertension and started on labetalol 100 mg bid. C-section was performed without any complications, and patient was discharged from the hospital on labetalol for blood pressure control. She resumed her job as a healthcare provider in mid-December, and received her first dose of Pfizer-BioNTech COVID-19 vaccine on January 4th. After 1 week, she started developing generalized pruritus, then choluria, and finally noticed jaundice, presenting to the emergency room on day +13 after COVID-19 vaccination.
She had a normal physical exam, except for scleral icterus, jaundice and palpable hepatomegaly. In the emergency room, laboratories were significant for: bilirubin 4.8 mg/dl, AST 754 U/L, ALT 2,001 U/L, alkaline phosphatase 170 U/L, and ammonium 61 mg/dl. Laboratory results were negative for hepatitis A, B, and C, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV) type 1 and 2, and HIV. At the time of submission, HEV had not been tested. Antinuclear antibody (ANA) was positive (1:1,280; homogeneous pattern). Double-stranded DNA antibodies were also positive (1:80). Other antibodies (i.e. anti-mitochondrial, anti-smooth muscle, liver-kidney microsomal, antineutrophil cytoplasmic antibodies) were negative. Total IgG was 1,081 mg/dl (normal range: 694–1,618 mg/dl). Ceruloplasmin, transferrin saturation, alpha-1-antitrypsin, TSH, and serum protein electrophoresis were all normal. Abdominal ultrasound with Doppler reported hepatomegaly without cirrhotic morphology, and no intra- or extra-hepatic biliary dilation.
Endoscopic ultrasound showed no evidence of biliary lithiasis or biliary dilation, and transduodenal liver biopsies were obtained. In Fig. 1 A–D we have included the slides of her liver biopsy and a full description of the histology. Liver biopsy was consistent with drug/toxin related liver injury, autoimmune hepatitis or infectious related etiologies. A PAS-D stain, CMV & HSV 1/2 immunohistochemical stains, EBV by in situ hybridization (EBER-ISH) and Grocott methenamine special stain for fungi were all negative. Other than the COVID-19 vaccine and labetalol, no other drugs, herbal supplements or toxins were reported by the patient. The Revised Original Score for autoimmune hepatitis pretreatment was 18 (results >15 suggest definite autoimmune hepatitis). Fig. 1E summarizes plasma ALT, AST, and total bilirubin over time, before and after treatment with prednisone 20 mg daily.
To our knowledge, this is the first reported episode of autoimmune hepatitis developing post-COVID-19 vaccination, raising concern regarding the possibility of vaccine-induced autoimmunity. As causality cannot be proven, it is possible that this association is just coincidental. However, severe cases of SARS-CoV-2 infection are characterized by an autoinflammatory dysregulation that contributes to tissue damage.1 As the viral spike protein appears to be responsible for this,1 , 5 it is plausible that spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals. In support of this, several cases of ITP have been reported days after COVID-19 vaccination.6
Several atypical features of her presentation deserve further discussion. First, immunoglobulin G levels were not elevated as typically reported for autoimmune hepatitis. However, Hartl et al. recently reported that ~10% of patients with autoimmune hepatitis had normal immunoglobulin G levels at presentation.7 Second, histology revealed the presence of eosinophils, which are more commonly seen with drug or toxin induced liver injury. However, they can be found in cases of autoimmune hepatitis.8 It is also possible that we could be in the presence of a vaccine-related drug-induced liver injury with features of autoimmune hepatitis, as previously described for nitrofurantoin or minocycline.9 In line with this, the patient has already started a prednisone taper, as patients with well documented drug-induced AIH do not typically show relapses after steroid discontinuation.10 Finally, symptoms developed 6 days after vaccination, which instinctively appears as a short period of time. However, latency periods after vaccination of just days have been observed in prior reports.6 , 11
In summary, autoimmune hepatitis developed in a healthy 35-year-old female in her third month postpartum. Whether there exists a causal relationship between COVID-19 vaccination and the development of autoimmune hepatitis remains to be determined. We are hopeful that this manuscript will not discourage healthcare providers from getting and prescribing COVID-19 vaccines, but that it will raise awareness about potential side effects that will likely emerge as we continue to vaccinate more people. Only long-term follow-up of large cohorts of patients receiving the vaccine will answer the question as to whether it increases the risk of autoimmune conditions. Until then, healthcare providers are encouraged to remain vigilant.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/?source=patrick.net
11
Al_Sharpton_for_President
2022 May 8, 1:53pm
Al_Sharpton_for_President
2022 May 8, 1:53pm
Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine
Myasthenia gravis (MG) is an autoimmune disease that results in muscle weakness and fatigability. Extraocular involvement may be the first sign of disease. It may be triggered by infections, stress, or medications. We describe a first reported case of ocular MG induced by the viral vector Oxford-AstraZeneca coronavirus disease (COVID-19) vaccine, detail the pathophysiology of vaccine-induced MG, and explore the impact of COVID-19 on MG patients.
https://pubmed.ncbi.nlm.nih.gov/35499172/?source=patrick.net
Myasthenia gravis (MG) is an autoimmune disease that results in muscle weakness and fatigability. Extraocular involvement may be the first sign of disease. It may be triggered by infections, stress, or medications. We describe a first reported case of ocular MG induced by the viral vector Oxford-AstraZeneca coronavirus disease (COVID-19) vaccine, detail the pathophysiology of vaccine-induced MG, and explore the impact of COVID-19 on MG patients.
https://pubmed.ncbi.nlm.nih.gov/35499172/?source=patrick.net
12
Al_Sharpton_for_President
2022 May 8, 1:53pm
Al_Sharpton_for_President
2022 May 8, 1:53pm
Graves' Disease Following COVID-19 Vaccination
Autoimmune endocrine diseases have been reported after influenza and the human papillomavirus vaccine, but there is limited data on autoimmune diseases after coronavirus disease 2019 (COVID-19) vaccination. Our report is about a 42-year-old Caucasian male and a 68-year-old Caucasian female who developed Graves' disease after receiving Moderna (Moderna, Inc., Cambridge, Massachusetts, United States) and Johnson & Johnson (Johnson & Johnson, New Brunswick, New Jersey, United States) vaccines, respectively. Both patients had no previous autoimmune thyroiditis and had normal thyroid function but developed hyperthyroidism characterized by suppressed thyroid-stimulating hormone (TSH), elevated free T4 level, and TSH receptor antibodies after vaccination. COVID-19 vaccines, either mRNA-based (Moderna) or non-mRNA-based (Johnson & Johnson), can cause Graves' disease. The clinical manifestations are similar to Graves' disease but without ocular manifestations.
https://pubmed.ncbi.nlm.nih.gov/35497078/?source=patrick.net
Autoimmune endocrine diseases have been reported after influenza and the human papillomavirus vaccine, but there is limited data on autoimmune diseases after coronavirus disease 2019 (COVID-19) vaccination. Our report is about a 42-year-old Caucasian male and a 68-year-old Caucasian female who developed Graves' disease after receiving Moderna (Moderna, Inc., Cambridge, Massachusetts, United States) and Johnson & Johnson (Johnson & Johnson, New Brunswick, New Jersey, United States) vaccines, respectively. Both patients had no previous autoimmune thyroiditis and had normal thyroid function but developed hyperthyroidism characterized by suppressed thyroid-stimulating hormone (TSH), elevated free T4 level, and TSH receptor antibodies after vaccination. COVID-19 vaccines, either mRNA-based (Moderna) or non-mRNA-based (Johnson & Johnson), can cause Graves' disease. The clinical manifestations are similar to Graves' disease but without ocular manifestations.
https://pubmed.ncbi.nlm.nih.gov/35497078/?source=patrick.net
13
Al_Sharpton_for_President
2022 May 8, 1:55pm
Al_Sharpton_for_President
2022 May 8, 1:55pm
Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma
While the global pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is still ongoing and new virus variants are emerging, there is a universal need for vaccines to protect individuals from severe complications and ideally control the pandemic by enabling herd immunity. Several vaccines against SARS-CoV-2 have been approved and are widely used to stem the recurring waves of coronavirus disease 2019 (COVID-19). Post-marketing surveillance is essential to record even rare safety issues related to these new vaccines. Among these issues, several autoimmune phenomena have been recorded in temporal association with and feasibly triggered by a vaccination.
Acquired haemophilia A (AHA) is a rare condition characterized by new-onset haemorrhagic diathesis caused by an inhibitor of blood clotting factor VIII (FVIII), often in the elderly and most commonly associated with autoimmune or malignant disease. There have been a small number of AHA cases triggered by vaccinations, including those against SARS-CoV-2. We report the first case of AHA in temporal association with an mRNA-1273 booster vaccination. The diagnosis was made promptly, and the patient received appropriate care including immunosuppression using glucocorticoids, cyclophosphamide (CYC) and rituximab (RTX). The haemorrhage ceased after escalation of treatment, and the patient is recovering. Concurrent malignancy was initially ruled out using a wide scope of diagnostic tests, but pleomorphic dermal sarcoma (PDS) of the forehead occurred after initiation of specific AHA immunosuppressive treatment. Since large vaccination programs are ongoing worldwide and potential adverse events during post-marketing surveillance have been reported following vaccination against SARS-CoV-2, this case illustrates challenges in rare events occurring in association with SARS-CoV-2 vaccination and to proof a causal relationship. Therefore, there is an urgent need for reporting any events in association with SARS-CoV-2 vaccination, but also a crucial discussion about possible concurrent triggers and follow-up information about individual patients.
https://pubmed.ncbi.nlm.nih.gov/35479071/?source=patrick.net
While the global pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is still ongoing and new virus variants are emerging, there is a universal need for vaccines to protect individuals from severe complications and ideally control the pandemic by enabling herd immunity. Several vaccines against SARS-CoV-2 have been approved and are widely used to stem the recurring waves of coronavirus disease 2019 (COVID-19). Post-marketing surveillance is essential to record even rare safety issues related to these new vaccines. Among these issues, several autoimmune phenomena have been recorded in temporal association with and feasibly triggered by a vaccination.
Acquired haemophilia A (AHA) is a rare condition characterized by new-onset haemorrhagic diathesis caused by an inhibitor of blood clotting factor VIII (FVIII), often in the elderly and most commonly associated with autoimmune or malignant disease. There have been a small number of AHA cases triggered by vaccinations, including those against SARS-CoV-2. We report the first case of AHA in temporal association with an mRNA-1273 booster vaccination. The diagnosis was made promptly, and the patient received appropriate care including immunosuppression using glucocorticoids, cyclophosphamide (CYC) and rituximab (RTX). The haemorrhage ceased after escalation of treatment, and the patient is recovering. Concurrent malignancy was initially ruled out using a wide scope of diagnostic tests, but pleomorphic dermal sarcoma (PDS) of the forehead occurred after initiation of specific AHA immunosuppressive treatment. Since large vaccination programs are ongoing worldwide and potential adverse events during post-marketing surveillance have been reported following vaccination against SARS-CoV-2, this case illustrates challenges in rare events occurring in association with SARS-CoV-2 vaccination and to proof a causal relationship. Therefore, there is an urgent need for reporting any events in association with SARS-CoV-2 vaccination, but also a crucial discussion about possible concurrent triggers and follow-up information about individual patients.
https://pubmed.ncbi.nlm.nih.gov/35479071/?source=patrick.net
15
Al_Sharpton_for_President
2022 May 8, 4:04pm
Al_Sharpton_for_President
2022 May 8, 4:04pm
Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA vaccine: A case report and brief literature review
Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta-haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid-19 vaccines is rarely reported. We describe an original clinical observation of a 75-year-old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.
https://pubmed.ncbi.nlm.nih.gov/35434826/?source=patrick.net
Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta-haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid-19 vaccines is rarely reported. We describe an original clinical observation of a 75-year-old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.
https://pubmed.ncbi.nlm.nih.gov/35434826/?source=patrick.net
16
Al_Sharpton_for_President
2022 May 8, 4:05pm
Al_Sharpton_for_President
2022 May 8, 4:05pm
Two Case Reports of Subacute Thyroiditis after Receiving Vaccine for COVID-19
The ongoing COVID-19 pandemic, caused by a coronavirus named SARS-CoV-2, has struck the planet with great force. As of December 2019, the virus has made its devasting route across all continents . In January 2022, the World Health Organization (WHO) registered over 5.5 million COVID-19 related deaths. Most of these people had suffered from pneumonia and acute respiratory distress syndrome , and in some cases, extensive damage to all organ systems.
To get hold of this pandemic, it was vital to find effective vaccines against it. The two vaccine candidates BNT162b2 (BioNTech/Pfizer) and ChAdOx1 (University of Oxford and AstraZeneca) offer a high level of protection against COVID-19 by providing immunity due to antibody production against the spike protein of SARS-CoV-2. In addition to general side effects, immunological side effects such as subacute thyroiditis can follow the vaccination. This transient inflammatory condition of the thyroid gland is characterized with hyperthyroxinemia, inflammation, pain, and tenderness in the thyroid region, as well as an elevation of serum thyroglobulin concentration.
There are only a few reports on the occurrence of this disease after receiving a COVID-19 vaccine. We present two cases of subacute thyroiditis after vaccination with the vaccines BNT162b2 and ChAdOx1 and try to enlighten the problem of immunological phenomena after vaccination. It must be discussed whether cross-reactivity of the spike protein and tissue proteins such as thyroid peroxidase (TPO), an "autoimmune/inflammatory syndrome by adjuvants" (ASIA), or the circulating spike protein itself after vaccination are responsible for the SAT.
https://pubmed.ncbi.nlm.nih.gov/35433060/?source=patrick.net
The ongoing COVID-19 pandemic, caused by a coronavirus named SARS-CoV-2, has struck the planet with great force. As of December 2019, the virus has made its devasting route across all continents . In January 2022, the World Health Organization (WHO) registered over 5.5 million COVID-19 related deaths. Most of these people had suffered from pneumonia and acute respiratory distress syndrome , and in some cases, extensive damage to all organ systems.
To get hold of this pandemic, it was vital to find effective vaccines against it. The two vaccine candidates BNT162b2 (BioNTech/Pfizer) and ChAdOx1 (University of Oxford and AstraZeneca) offer a high level of protection against COVID-19 by providing immunity due to antibody production against the spike protein of SARS-CoV-2. In addition to general side effects, immunological side effects such as subacute thyroiditis can follow the vaccination. This transient inflammatory condition of the thyroid gland is characterized with hyperthyroxinemia, inflammation, pain, and tenderness in the thyroid region, as well as an elevation of serum thyroglobulin concentration.
There are only a few reports on the occurrence of this disease after receiving a COVID-19 vaccine. We present two cases of subacute thyroiditis after vaccination with the vaccines BNT162b2 and ChAdOx1 and try to enlighten the problem of immunological phenomena after vaccination. It must be discussed whether cross-reactivity of the spike protein and tissue proteins such as thyroid peroxidase (TPO), an "autoimmune/inflammatory syndrome by adjuvants" (ASIA), or the circulating spike protein itself after vaccination are responsible for the SAT.
https://pubmed.ncbi.nlm.nih.gov/35433060/?source=patrick.net
17
Al_Sharpton_for_President
2022 May 8, 4:06pm
Al_Sharpton_for_President
2022 May 8, 4:06pm
Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases
Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We hypothesized that vaccination against coronavirus disease 2019 (COVID-19) could trigger an immunological response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. Clinical and histopathological examinations confirmed the diagnosis of bullous pemphigoid (BP) in three patients and pemphigus in the other two. According to the French method of imputability, the pharmacovigilance investigation showed an I5B4 causality assessment score for the vaccines, interpreted as highly probable, for all the patients. The diagnosis of vaccine-induced autoimmune bullous dermatosis was highly suspected. One patient's condition improved by dermocorticoids alone, while the other four required oral corticosteroid therapy at 0.5 mg/kg/day, which led to a favorable outcome.
https://pubmed.ncbi.nlm.nih.gov/35425676/?source=patrick.net
Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We hypothesized that vaccination against coronavirus disease 2019 (COVID-19) could trigger an immunological response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. Clinical and histopathological examinations confirmed the diagnosis of bullous pemphigoid (BP) in three patients and pemphigus in the other two. According to the French method of imputability, the pharmacovigilance investigation showed an I5B4 causality assessment score for the vaccines, interpreted as highly probable, for all the patients. The diagnosis of vaccine-induced autoimmune bullous dermatosis was highly suspected. One patient's condition improved by dermocorticoids alone, while the other four required oral corticosteroid therapy at 0.5 mg/kg/day, which led to a favorable outcome.
https://pubmed.ncbi.nlm.nih.gov/35425676/?source=patrick.net
18
Al_Sharpton_for_President
2022 May 8, 4:08pm
Al_Sharpton_for_President
2022 May 8, 4:08pm
Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine
Purpose: To describe a case of anterior scleritis related to SARS-CoV-2 vaccine. SARS-CoV-2 vaccines appear safe; however vaccination has triggered thromboembolic events in predisposed patients.
Methods: A retrospective case report of anterior scleritis in a woman following administration of both ChAdOx1nCoV-19 vaccine doses was studied by complete ophthalmologic examination and complementary tests.
Results: The patient has overcome SARS-CoV-2 infection a year prior. Ancillary tests including autoimmune and infectious diseases were negative. The chronology between ChAdOx1nCoV-19 vaccine and the sequential episodes of scleritis may have a cause-and-effect relationship.
Conclusion: Ophthalmologists may be aware of scleritis as an ocular manifestation following ChAdOx1nCoV-19 vaccine, in otherwise healthy patients.
Keywords: AstraZeneca vaccine; COVID-19; ChAdOx1nCoV-19; SARS-CoV-2; scleritis; vasculitis.
https://pubmed.ncbi.nlm.nih.gov/35394853/?source=patrick.net
Purpose: To describe a case of anterior scleritis related to SARS-CoV-2 vaccine. SARS-CoV-2 vaccines appear safe; however vaccination has triggered thromboembolic events in predisposed patients.
Methods: A retrospective case report of anterior scleritis in a woman following administration of both ChAdOx1nCoV-19 vaccine doses was studied by complete ophthalmologic examination and complementary tests.
Results: The patient has overcome SARS-CoV-2 infection a year prior. Ancillary tests including autoimmune and infectious diseases were negative. The chronology between ChAdOx1nCoV-19 vaccine and the sequential episodes of scleritis may have a cause-and-effect relationship.
Conclusion: Ophthalmologists may be aware of scleritis as an ocular manifestation following ChAdOx1nCoV-19 vaccine, in otherwise healthy patients.
Keywords: AstraZeneca vaccine; COVID-19; ChAdOx1nCoV-19; SARS-CoV-2; scleritis; vasculitis.
https://pubmed.ncbi.nlm.nih.gov/35394853/?source=patrick.net
19
Al_Sharpton_for_President
2022 May 8, 4:09pm
Al_Sharpton_for_President
2022 May 8, 4:09pm
Reversible neurological and brain MRI changes following COVID-19 vaccination: A case report
Background: Various neurological sequalae have been described following COVID-19 vaccination. Here we describe the first case of untreated post COVID-19 vaccine encephalitis with spontaneous resolution of contrast enhancing hyperintensities on MRI concomitant with clinical improvement.
Case presentation: A 59-year-old woman presented with a two-day history of unsteady gait, incoordination, visual symptoms, and lethargy. She had received AZD1222 (AstraZeneca) and mRNA-1273 (Moderna) COVID-19 vaccines at 3 months and 12 days, respectively, before presentation. Brain MRI showed no abnormality on the non-enhanced sequences, but numerous enhancing lesions in the cerebral cortex, deep grey matter, brainstem, and cerebellum. Treatment was expectant, the patient improved clinically over 10 days, and repeat MRI showed near complete resolution of the imaging abnormality.
Conclusions: We describe neurological deterioration 12 days after a second dose of COVID-19 vaccine. There was no evidence of edema or demyelinating lesions in the brain on MRI, but there was extensive contrast-enhancement indicating loss of blood-brain barrier (BBB) integrity. This provides a potential in vivo, clinical-imaging correlate of the post-mortem evidence that SARS-CoV-2 spike protein may induce loss of BBB permeability. While this adds to the list of rare adverse neurological reactions to COVID-19 vaccination, the benefits of receiving the vaccine far outweigh these risks.
https://pubmed.ncbi.nlm.nih.gov/35381296/?source=patrick.net
Background: Various neurological sequalae have been described following COVID-19 vaccination. Here we describe the first case of untreated post COVID-19 vaccine encephalitis with spontaneous resolution of contrast enhancing hyperintensities on MRI concomitant with clinical improvement.
Case presentation: A 59-year-old woman presented with a two-day history of unsteady gait, incoordination, visual symptoms, and lethargy. She had received AZD1222 (AstraZeneca) and mRNA-1273 (Moderna) COVID-19 vaccines at 3 months and 12 days, respectively, before presentation. Brain MRI showed no abnormality on the non-enhanced sequences, but numerous enhancing lesions in the cerebral cortex, deep grey matter, brainstem, and cerebellum. Treatment was expectant, the patient improved clinically over 10 days, and repeat MRI showed near complete resolution of the imaging abnormality.
Conclusions: We describe neurological deterioration 12 days after a second dose of COVID-19 vaccine. There was no evidence of edema or demyelinating lesions in the brain on MRI, but there was extensive contrast-enhancement indicating loss of blood-brain barrier (BBB) integrity. This provides a potential in vivo, clinical-imaging correlate of the post-mortem evidence that SARS-CoV-2 spike protein may induce loss of BBB permeability. While this adds to the list of rare adverse neurological reactions to COVID-19 vaccination, the benefits of receiving the vaccine far outweigh these risks.
https://pubmed.ncbi.nlm.nih.gov/35381296/?source=patrick.net
20
Al_Sharpton_for_President
2022 May 8, 4:11pm
Al_Sharpton_for_President
2022 May 8, 4:11pm
Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases
Background: Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases.
Methods: Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of de novo GN within native kidney biopsies and one disease flare in an allograft.
Results: The patients with collapsing glomerulopathy were of Black descent and had two APOL1 genomic risk alleles. A brief literature review of patient reports and small series is also provided to include all reported cases to date (n=52). The incidence of induction of glomerular disease in response to SARS-CoV-2 immunization is unknown; however, there was no overall increase in incidence of glomerular disease when compared with the 2 years prior to the COVID-19 pandemic diagnosed on kidney biopsies in our practice.
Conclusions: Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.
Keywords: ANCA; APOL1; COVID-19; IgA nephropathy; SARS-CoV-2 vaccine; collapsing glomerulopathy; crescentic glomerulonephritis; glomerular and tubulointerstitial diseases; lupus nephritis; membranous nephropathy; minimal change disease.
https://pubmed.ncbi.nlm.nih.gov/35372991/?source=patrick.net
Background: Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases.
Methods: Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of de novo GN within native kidney biopsies and one disease flare in an allograft.
Results: The patients with collapsing glomerulopathy were of Black descent and had two APOL1 genomic risk alleles. A brief literature review of patient reports and small series is also provided to include all reported cases to date (n=52). The incidence of induction of glomerular disease in response to SARS-CoV-2 immunization is unknown; however, there was no overall increase in incidence of glomerular disease when compared with the 2 years prior to the COVID-19 pandemic diagnosed on kidney biopsies in our practice.
Conclusions: Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.
Keywords: ANCA; APOL1; COVID-19; IgA nephropathy; SARS-CoV-2 vaccine; collapsing glomerulopathy; crescentic glomerulonephritis; glomerular and tubulointerstitial diseases; lupus nephritis; membranous nephropathy; minimal change disease.
https://pubmed.ncbi.nlm.nih.gov/35372991/?source=patrick.net
21
Al_Sharpton_for_President
2022 May 8, 4:12pm
Al_Sharpton_for_President
2022 May 8, 4:12pm
Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: A case report
Acute disseminated encephalomyelitis (ADEM) is an acute demyelinating disorder of the central nervous system that is ordinarily monophasic. ADEM can develop following infection or vaccination. Here, we present a 37 y/o male patient with progressive muscle weakness in all limbs along with dysphagia following COVID-19 vaccination. Brain magnetic resonance imaging (MRI) revealed typical imaging findings which presented as multifocal T2-FLAIR signal changes in the corticospinal tract, pons, and temporal lobe with diffusion restriction. Magnetic resonance spectroscopy (MRS) further confirmed the diagnosis by the typical elevation of the Choline and Myoinositol peaks. Neurologic impairments have been reported as the potential side effects of COVID-19 vaccines. Appropriate imaging modalities together with a thorough clinical examination are essential for making a correct diagnosis.
https://pubmed.ncbi.nlm.nih.gov/35355527/?source=patrick.net
Acute disseminated encephalomyelitis (ADEM) is an acute demyelinating disorder of the central nervous system that is ordinarily monophasic. ADEM can develop following infection or vaccination. Here, we present a 37 y/o male patient with progressive muscle weakness in all limbs along with dysphagia following COVID-19 vaccination. Brain magnetic resonance imaging (MRI) revealed typical imaging findings which presented as multifocal T2-FLAIR signal changes in the corticospinal tract, pons, and temporal lobe with diffusion restriction. Magnetic resonance spectroscopy (MRS) further confirmed the diagnosis by the typical elevation of the Choline and Myoinositol peaks. Neurologic impairments have been reported as the potential side effects of COVID-19 vaccines. Appropriate imaging modalities together with a thorough clinical examination are essential for making a correct diagnosis.
https://pubmed.ncbi.nlm.nih.gov/35355527/?source=patrick.net
22
Al_Sharpton_for_President
2022 May 8, 4:13pm
Al_Sharpton_for_President
2022 May 8, 4:13pm
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand?
The devastating characteristic of COVID-19 pandemic calls for immediate and effective solutions to tackle it. Vaccines seem to be the only promising and effective way to fight against the novel coronavirus - even against new mutated variants. Because of the rapid development and distribution of numerous COVID-19 vaccines in different platforms, meticulous evaluation of vaccines' safety is more critical than ever - especially given the fact that most of the candidates have not completed the clinical phase.
Therefore, to optimize the vaccines' safety and efficacy, it is highly important to carefully report and scientifically discuss the serious adverse effects following vaccination. In this respect, we discuss different neurological and neuropsychological adverse effects of COVID-19 vaccines including demyelinating diseases, Bell's palsy (BP), cerebrovascular complications, seizures, functional neurological disorders (FNDs), and some other rare adverse events, and hypothetical mechanisms which can lead to the reported side effects. Given the fact that the incidence of such events are rare and most of them are treatable, the current review aims to shed light on how much the relationship between COVID-19 vaccines and these complications can be reliable and provide an insight for future studies with much more meticulous methodologies to discuss the possible correlational or causal relationship between these complications and COVID-19 vaccines and elucidate whether or not the neurological side effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines can count as a considerable threat to public health.
Keywords: COVID-19 vaccines; SARS-CoV-2; cerebrovascular complications; demyelinating diseases; neurological complications.
https://pubmed.ncbi.nlm.nih.gov/35334195/?source=patrick.net
The devastating characteristic of COVID-19 pandemic calls for immediate and effective solutions to tackle it. Vaccines seem to be the only promising and effective way to fight against the novel coronavirus - even against new mutated variants. Because of the rapid development and distribution of numerous COVID-19 vaccines in different platforms, meticulous evaluation of vaccines' safety is more critical than ever - especially given the fact that most of the candidates have not completed the clinical phase.
Therefore, to optimize the vaccines' safety and efficacy, it is highly important to carefully report and scientifically discuss the serious adverse effects following vaccination. In this respect, we discuss different neurological and neuropsychological adverse effects of COVID-19 vaccines including demyelinating diseases, Bell's palsy (BP), cerebrovascular complications, seizures, functional neurological disorders (FNDs), and some other rare adverse events, and hypothetical mechanisms which can lead to the reported side effects. Given the fact that the incidence of such events are rare and most of them are treatable, the current review aims to shed light on how much the relationship between COVID-19 vaccines and these complications can be reliable and provide an insight for future studies with much more meticulous methodologies to discuss the possible correlational or causal relationship between these complications and COVID-19 vaccines and elucidate whether or not the neurological side effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines can count as a considerable threat to public health.
Keywords: COVID-19 vaccines; SARS-CoV-2; cerebrovascular complications; demyelinating diseases; neurological complications.
https://pubmed.ncbi.nlm.nih.gov/35334195/?source=patrick.net
23
Al_Sharpton_for_President
2022 May 8, 4:15pm
Al_Sharpton_for_President
2022 May 8, 4:15pm
Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult
The coronavirus disease (COVID-19 or SARS-CoV-2) pandemic has brought the global community to a halt. A return to normalcy is dependent on effective reopening strategies that encourage herd immunity through the implementation of vaccines. Cardiopulmonary inflammation has been reported in SARS-CoV-2 infection, independent of the severity, mainly amongst the juvenile population. Cardiovascular involvement following SARS-CoV-2 infection is associated with higher mortality and morbidity. Cardiovascular complications following COVID-19 vaccination have been documented as less severe, with no link between cardiovascular injury and death.
This case report describes the presentation of an otherwise healthy 18-year-old male who experienced retrosternal chest pain after receiving a first dose of the mRNA-1273 vaccine. The patient had a negative polymerase chain reaction (PCR) test for COVID-19 infection. An electrocardiogram revealed diffuse ST elevation and PR segment depression, with increased inflammatory markers consistent with pericarditis. Elevation of troponin (16 ng/mL), evidence of borderline reduced ejection fraction (50-55%), and global left ventricular hypokinesis were suggestive of myopericarditis. Infectious and autoimmune studies were negative. The patient was treated mainly with non-steroidal anti-inflammatory drugs and colchicine, which resulted in a significant improvement of clinical symptoms. As the administration of emergency COVID-19 vaccines continues worldwide, it is of paramount importance to be aware of possible adverse events, including those affecting the cardiovascular system.
Keywords: covid 19; covid-19 vaccine; myo-pericarditis; side effects of medical treatment; young population.
https://pubmed.ncbi.nlm.nih.gov/35308760/?source=patrick.net
The coronavirus disease (COVID-19 or SARS-CoV-2) pandemic has brought the global community to a halt. A return to normalcy is dependent on effective reopening strategies that encourage herd immunity through the implementation of vaccines. Cardiopulmonary inflammation has been reported in SARS-CoV-2 infection, independent of the severity, mainly amongst the juvenile population. Cardiovascular involvement following SARS-CoV-2 infection is associated with higher mortality and morbidity. Cardiovascular complications following COVID-19 vaccination have been documented as less severe, with no link between cardiovascular injury and death.
This case report describes the presentation of an otherwise healthy 18-year-old male who experienced retrosternal chest pain after receiving a first dose of the mRNA-1273 vaccine. The patient had a negative polymerase chain reaction (PCR) test for COVID-19 infection. An electrocardiogram revealed diffuse ST elevation and PR segment depression, with increased inflammatory markers consistent with pericarditis. Elevation of troponin (16 ng/mL), evidence of borderline reduced ejection fraction (50-55%), and global left ventricular hypokinesis were suggestive of myopericarditis. Infectious and autoimmune studies were negative. The patient was treated mainly with non-steroidal anti-inflammatory drugs and colchicine, which resulted in a significant improvement of clinical symptoms. As the administration of emergency COVID-19 vaccines continues worldwide, it is of paramount importance to be aware of possible adverse events, including those affecting the cardiovascular system.
Keywords: covid 19; covid-19 vaccine; myo-pericarditis; side effects of medical treatment; young population.
https://pubmed.ncbi.nlm.nih.gov/35308760/?source=patrick.net
The doctors told him his body’s immune response attacked his own organs, historically some type of 1 in 100 million ailment.
The doctors were telling him this condition has been popping up at a much higher rate, like 1 in a few hundred thousand, after taking booster shots.
After hearing this, my buddy asks them if they think the booster killed his father. They said yes, but their opinions on the booster had to be kept private and no mention was allowed in official death documents.
They’re fucking killing people and doctors care more about their professional future than death.